Meeder Asset Management’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-267
| Closed | -$27.2K | – | 602 |
|
|
2023
Q2 | $27.2K | Buy |
+267
| New | +$25.3K | ﹤0.01% | 419 |
|
|
2021
Q4 | – | Sell |
-11
| Closed | -$1K | – | 2483 |
|
|
2021
Q3 | $1K | Hold |
11
| – | – | ﹤0.01% | 2409 |
|
|
2021
Q2 | $2K | Hold |
11
| – | – | ﹤0.01% | 2273 |
|
|
2021
Q1 | $1K | Hold |
11
| – | – | ﹤0.01% | 2289 |
|
|
2020
Q4 | $1K | Hold |
11
| – | – | ﹤0.01% | 1778 |
|
|
2020
Q3 | $1K | Sell |
11
-35
| -76% | -$4.37K | ﹤0.01% | 2079 |
|
|
2020
Q2 | $7K | Sell |
46
-4
| -8% | -$608 | ﹤0.01% | 1447 |
|
|
2020
Q1 | $7K | Sell |
50
-890
| -95% | -$172K | ﹤0.01% | 1679 |
|
|
2019
Q4 | $193K | Buy |
+940
| New | +$171K | 0.01% | 612 |
|
|
2019
Q3 | – | Sell |
-360
| Closed | -$34K | – | 2301 |
|
|
2019
Q2 | $34K | Sell |
360
-440
| -55% | -$38K | ﹤0.01% | 1063 |
|
|
2019
Q1 | $69K | Sell |
800
-669
| -46% | -$55.5K | 0.01% | 793 |
|
|
2018
Q4 | $82K | Buy |
1,469
+556
| +61% | +$33.9K | 0.01% | 689 |
|
|
2018
Q3 | $75K | Buy |
+913
| New | +$64.3K | 0.01% | 700 |
|
|
2018
Q1 | – | Sell |
-53
| Closed | -$2K | – | 1791 |
|
|
2017
Q4 | $2K | Hold |
53
| – | – | ﹤0.01% | 1519 |
|
|
2017
Q3 | $2K | Buy |
+53
| New | +$1.59K | ﹤0.01% | 1496 |
|
|
2017
Q2 | – | Sell |
-30
| Closed | -$1K | – | 1938 |
|
|
2017
Q1 | $1K | Buy |
+30
| New | +$741 | ﹤0.01% | 1579 |
|
Other funds holding RETA
Meeder Asset Management's RETA Position: Q3 2023 in Review
Meeder Asset Management sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 267 shares — an estimated $27.2K sold.
Meeder Asset Management first reported a position in RETA in Q1 2017 and held it in 16 quarters. The position peaked at $193K in Q4 2019. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.
- Meeder Asset Management reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
- Meeder Asset Management sold 267 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $27.2K.
- Meeder Asset Management first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q1 2017 and held it in 16 quarters.
- Meeder Asset Management's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $193K in Q4 2019.
- 2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.
Based on Meeder Asset Management's 13F filing for Q3 2023, filed 13 Nov 2023.